Highlight Therapeutics (Madrid, Spain) develops nanocomplexes of synthetic dsRNA that target PAMP receptors and TLRs to induce powerful immune responses. Bioncotech is clinically evaluating several immune-oncology combinations with its lead product. — Highlighttherapeutics.com
Location: Spain
Total raised: $17.54M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.09.2025 | - | $17.54M | - |
Mentions in press and media 15
| Date | Title | Description |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 19.03.2026 | German Biotech Kupando Secures €10M for Advanced Immunotherapy Pipeline | Kupando, a prominent German biotech firm, recently announced substantial new financing. The company secured an additional €10 million in Series A funding. This latest capital infusion elevates its total Series A funding to €23 million. The ... |
| 18.03.2026 | Inspired by animal immunity, Germany’s Kupando raises €10 million for cancer therapy | Schönefeld-based Kupando, a biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained immunity for use in oncology and infectious diseases, has secured an additional €10 million in Series A f... |
| 20.02.2026 | Cancer and immunology player Umlaut.bio adds funding to reach ~€3 million pre-Seed total | Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying small molecules, announced the extension of its pre-Seed financing to ~€3 million through the support of BaseLaunch. This addition not only helps to ac... |
| 16.09.2025 | Spanish cancer startup Highlight Therapeutics closes €15 million round to further skin tumour treatment | Valencia’s Highlight Therapeutics, a biopharmaceutical company focused on the development of next-generation immunotherapies, has raised €15 million aimed at strengthening their position in the treatment of skin tumours and accelerating its... |
| 13.04.2022 | Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR | BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD-1 treatment Primary endpoint met with a 30% Response Rate, 15% Complete Responses (CR)... |
| 15.03.2022 | Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 | MADRID, Spain, March 15, 2022 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced an oral presentation at the Combina... |
| 02.12.2021 | Highlight Therapeutics: BO-112 published in JITC | Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 results of BO-112 + pembrolizumab in melanoma at SITC MADRID, ... |
| 13.11.2021 | Résultats positifs de la phase 2b pour le mélanome en 2e ligne | Highlight Therapeutics annonce les résultats préliminaires positifs de l'étude de phase 2b sur le BO-112 + anti-PD1 chez des patients atteints de mélanome dont la maladie avait progressé avec l'anti-PD1 de manière confirmée lors de la SITC ... |
| 12.11.2021 | Positive Phase 2b results in 2nd line melanoma | BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD1 treatment Primary endpoint met with a 27% Overall Response Rate (ORR), 8% Complete Re... |
Show more